A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Exclusion Criteria

• •Uncomplicated skin and skin structure infection
• •ABSSSI due to or associated with disallowed etiology per protocol
• •Received antibacterial therapy for treatment of the current episode of ABSSSI except 1) \<48 hours of antibacterial therapy with a short-acting antibacterial drug, or 2) response is considered to be failure (no improvement in signs and symptoms) after at least 48 hours of therapy
• •Known bacteremia, severe sepsis, or septic shock
• •Significant or life-threatening condition, disease, or organ system condition
• •Recent history of opportunistic infections where the underlying cause of the infection is still active, or is suspected to be at risk of opportunistic infection with unusual pathogens
• •Received or is receiving treatment for active tuberculosis within 1 month of study start
• •Known or suspected severe neutropenia
• •Human immunodeficiency virus (HIV) positive and has Cluster of Differentiation (CD) 4 cell count \<15% (HIV testing is not required for eligibility)
• •Renal impairment that requires renal filtration
• •Severe hepatic impairment
• •Cardiac or electrocardiogram (ECG) finding that would limit participation in the study
• •Received an investigational medicinal product (not approved) within 30 days before study start
• •Investigational device present or removed within 30 days before study start
• •Previously treated with tedizolid phosphate
• •Contraindication, including hypersensitivity to tedizolid phosphate, other oxazolidinones, or any component in the formulation
• •Contraindication, including hypersensitivity to all available comparator drugs
• •Wound infection and history of hypersensitivity to aztreonam adjunctive therapy or metronidazole adjunctive therapy, if adjunctive therapy is required
• •Needs oral administration of methotrexate, topotecan, irinotecan, or rosuvastatin, during administration of oral study drug (administration during the follow-up period, ie, after the end of treatment (EOT) visit, is allowed, as is administration during treatment with IV drug)
• •Female who is pregnant or nursing or is of childbearing potential and not abstinent; or male who is not abstinent
• •Use of monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective serotonin reuptake inhibitors, or serotonin 5-hydroxytryptamine receptor agonists (triptans)
• •Identified as having used illicit drugs (urine drug screening not required for entry)